Trends in utilization and off-label use of polyethylene glycol 4000 laxatives and the prevalence of constipation in children in France

OXON Epidemiology, Madrid, Spain, and London, UK
Clinical and Experimental Gastroenterology 07/2011; 4:181-8. DOI: 10.2147/CEG.S23055
Source: PubMed


To determine trends in utilization and off-label use of polyethylene glycol (PEG) 4000 in children and to determine the prevalence of constipation.
Retrospective cross-sectional analyses were conducted from 1997 to 2007 in a French health care database comprising general practitioners and pediatricians. Patients prescribed PEG 4000 (Forlax(®); Ipsen Pharma, Paris, France) were used to assess PEG 4000 use; constipation was defined by a diagnosis of constipation or use of any laxative. Analyses used linear regression models to fit trends over time.
The study sample consisted of a nationally representative sample of 1200 general practitioners with 1.6 million patient medical records and 100 pediatricians with 70,000 patient medical records. Data were available from 1997 to 2007 for general practitioners and from 2003 to 2007 for pediatricians and were extrapolated to the national level. Among both groups of physicians there were statistically significant increases in the number of patients prescribed 4 g. For the 10 g dose, there was a decline among pediatricians. The largest increases were in children aged 0-8 years and in females. The prevalence of constipation in children aged 0-18 years was 4%.
There has been an increase in the use of PEG 4000 laxative in children, particularly in the younger ages and in females. Use of the 4 g dose has increased. There was considerable off-label use of PEG 4000 in children aged 0-8 years before the introduction of the 4 g pediatric dose, which reflected clinical need.

Download full-text


Available from: Ignacio Méndez, Oct 06, 2015
10 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Constipation is a common problem in children worldwide. It can also be a chronic problem persisting for many months to years. Successful treatment of constipation requires long-term use of laxatives. Commonly used laxatives in children include milk of magnesia, lactulose, mineral oil, and polyethylene glycol. Compared to other laxatives, polyethylene glycol (with and without electrolytes) is a relatively new laxative used over the last decade. Recent studies report excellent efficacy and safety of polyethylene glycol for the long-term treatment of constipation in children. Due to excellent patient acceptance, polyethylene glycol has become a preferred choice of laxative for many practitioners. This article reviews the recently published pediatric literature on biochemistry, efficacy, safety, patient acceptance, and pharmacoeconomics of polyethylene glycol.
    Journal of pediatric gastroenterology and nutrition 04/2013; 57(2). DOI:10.1097/MPG.0b013e318296404a · 2.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To provide current information on off-label medication use in pediatric gastroenterology, including a discussion on US legislative efforts to address the issue. Medications used to treat pediatric gastrointestinal illnesses are frequently prescribed off-label. Acid suppressors, antiemetics, laxatives, and antitumor necrosis factor therapies are types of medications frequently used off-label in the pediatric gastroenterology arena. Pediatric studies conducted under US Federal laws are generating much-needed data on the safety and effectiveness of medications used to treat pediatric patients. Moreover, a new US law, the Food and Drug Administration Safety and Innovation Act, may further the development of pediatric medications in part by requiring pediatric-specific study plans earlier in the overall drug development process. As of today, there still are gaps in our knowledge about these medications, including for the treatment of pediatric gastroenterology diseases. Medications are widely used off-label in pediatrics, including medications intended to treat gastrointestinal diseases, such as antitumor necrosis factor and laxatives. Although legislation is helping to generate and make available important information about pediatric medications, most still do not contain pediatric data. Therefore, providers need to understand the potential risks and benefits of prescribing off-label products to pediatric patients.
    Current opinion in pediatrics 08/2013; 25(5). DOI:10.1097/MOP.0b013e328363ed4e · 2.53 Impact Factor